Biomedical Imaging


Extract more from images
to drive Drug Discovery with AI

Ardigen Biomedical Imaging Unit enables the identification of small molecule drug candidates through its AI Technology Platform. The Platform integrates the most recent advancements in AI (computer vision and cheminformatics) with molecular biology and medicinal chemistry, bridging the gap between cell imaging and small molecule design. Our unique approach of combining molecular structures, high content screening (HCS) images, and omics data allows us to obtain reliable predictions of Modes of Action and other molecular properties, identify HCS hits, and predict hit candidates. Moreover, its generative component enables fast library design and accelerates the process of lead optimization.

Biomedical Imaging Platform Capabilities

Combine Varied Data Types Through Artificial Intelligence

Biomedical Imaging Platform at Any Stage of Your Research:

Our solution will improve your drug design process through seamless AI-lab integration. The AI platform is a comprehensive solution that fits into your drug discovery process and can be used out-of-the-box in every step of the process. We can increase your chances of obtaining a drug candidate that will successfully pass the clinical trials. Whether you are just starting your project and looking for compounds to screen, or if you have already gathered phenotypic screening outcomes, we can help.

With our platform you are able to:

  • find the targets and off-targets of your molecules;
  • narrow the chemical search space;
  • optimize your compounds to obtain the desired phenotype;
  • assign Mode of Action to chemical compounds.

Accelerate Drug Discovery Process

Drug discovery process with Biomedical Imaging Platform

As the standard drug design process is expensive and time-consuming, it can be improved with our AI-based solutions. Our Platform allows you to:

  • exhaustively explore the chemical space of up to ~10^8 molecules;
  • design focused libraries which can improve the hit rate to 40%;
  • carry out the in silico optimization process yielding optimized compounds in even 2 AI-lab cycles;
  • prevent undesired phenotypic effect at an early stage;
  • efficiently obtain outcomes from Cell Painting assays.

Increasing Your Success Rate with Solutions Tailored to Your Needs

What Level of Customization Do You Need?

Whether you are just starting or have been in the field for some time, we fit into your needs by providing two approaches to
collaboration. Our out-of-the-box Licensed Virtual Screening Platform gives you access to a cloud-based app as a ready-to-use
solution. Whereas, Our Customized Virtual Screening Service enables integration with your internal data, pipelines, and system to
maximize the utility of its usage.

Virtual Screening Platform

Licensed Virtual Screening Platform or Customized Virtual Screening Service

  • Licensed Virtual Screening Platform

  • Our platform can be delivered as a cloud-based app with
    intuitive modules for data management, experiments analysis,
    and results reporting. By uploading data to your private and
    secure account in the cloud, you can easily perform analyzes of
    HCS images and molecular structures using our AI-based
    features.
  • Customized Virtual Screening Service

  • If you are looking to integrate our AI features into your internal
    pipelines, we will delegate a team of experts to deploy the
    platform on your internal infrastructure. During the integration
    process, we will adapt the modules to best fit into your drug
    design process and provide training and support to ensure high
    usability of the platform.

Technology Stack

We offer fast and reliable solutions that can be deployed both on premise and in the cloud

Case Studies

Click on the button below and discover our solutions in detail

Our science

We are driven by science and collaborations!

Since 2015, we’ve had the opportunity to execute a variety of exciting and complex projects, both for our clients and internally.
A high degree of trust and confidentiality is the foundation for our business. That’s why we are always very excited to share the results of our scientific projects.
We publish and present materials, such as journal publications, posters, case studies and technical notes whenever possible, through which we aim to show the scope of our scientific team’s experience.

On demand webinars

AI methods in small molecule design
15 June 2021 AI methods in small molecule design

    From sequences to properties of proteins – Speed up your drug discovery process with AI
    27 April 2021 From sequences to properties of proteins – Speed up your drug discovery process with AI

      A single pixel is worth its weight in gold. Automatic microarray analysis platform
      17 March 2021 A single pixel is worth its weight in gold. Automatic microarray analysis platform

        Ardigen's Technical Blog

        Meet us at upcoming events

        • Coming soon
          4 October 2022
          UK, London
          ELRIG 2022
        • 18 September 2022
          USA, Boston
          SBI2
        • 26 -28 June
          PMWC 2022
        • 15-16 February 2022
          digital
          Boost your way to successful therapy. AI for Drug Discovery Days”
        • 23 - 26 June
          digital
          SLAS Europe 2021
        • 14 - 18 June
          digital
          PMWC 2021 COVID Virtual
        • 15 - 17 June
          digital
          Pharma R&D Week Virtual
        • 9-10 June
          digital
          Precision in Drug Discovery & Preclinical Virtual Summit
        • 17 - 19 May 2021
          Biomarkers Week
        • 14 April
          digital
          Spatial Biology Europe conference
        • 25 - 26 March
          digital
          AI in Healthcare & Pharma Virtual Summit

        Contact us

        Are you interested in Biomedical Imaging platform based solutions?

          • https://ardigen.com/wp-content/uploads/2021/05/michal_warchol-min-1.png Michał Warchoł, PhD General Director of Biomedical Imaging Unit
          Go up